Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
A therapeutic dose would be 20-40mcg per day but it is not uncommon for IPED users to use as much as 160mcg (Llewellyn, 2017)
Withdraw only with sterile instruments to prevent cross-contamination
Ongoing low-dose maintenance (experimental) Continuous dosing approach: Dose: 1-2mg daily OR 3-5mg 2-3x weekly Duration: Ongoing (not cycled) Goal: Maintain constant telomerase activation Status: Experimental, not from research protocols Rationale: Telomerase needs continuous activation to maintain telomere length Cyclic dosing may allow regression between cycles Low-dose continuous might provide stable benefits Similar to maintenance protocols for other peptides Continuous dosing options: Advantages of continuous: No "off" periods where benefits regress Potentially stronger cumulative anti-aging More like natural physiologic regulation Easier to stack with other peptides Disadvantages: Much higher annual cost ($1,800-3,600 vs $300-600) No long-term safety data Uncertain if better than cyclic approach Storage challenges (more reconstitution) Deviates from proven protocols Current recommendation: Stick with proven 10-day cycles for most users Consider continuous only if cyclic approach inadequate Start with standard protocol first Assess your individual response Consult with peptide-knowledgeable physician Use our peptide cycle planning guide to design your Epithalon protocol
Beneficiaries can find the formulary on Kaisers website
